Mylan named in class-action suit over EpiPen

MORGANTOWN, W.Va. — Mylan NV has been named in a class-action racketeering suit.

CNBC reports the suit stems from alleged price gauging for the auto-injector EpiPen used to counter deadly allergic reactions.

According to the outlet, “The suit alleges that the “skyrocketing” list price of EpiPen for consumers was the result of Mylan’s payments of rebates to pharmacy benefit managers — including CVS Caremark, Express Scripts and Optum Rx — which handle prescription drug benefit programs for insurance plans.”

The class-action racketeering suit was filed in U.S. District Court in Seattle, Washington on Monday, April 3.

Following criticism over pricing practices of its auto injection allergy drug, Mylan previously agreed to a settlement with the U.S. Department of Justice and federal regulators.

The price of Mylan’s EpiPen Auto-Injector including the EpiPen Jr. has increased more than 500 percent in nine years.